Dual Targeted Therapy
Cross-source consensus on Dual Targeted Therapy from 1 sources and 4 claims.
1 sources · 4 claims
Uses
How it works
Risks & contraindications
Comparisons
Highlighted claims
- Dual targeted therapy combines BRAF and MEK inhibition in the MAPK/ERK signalling cascade. — Dual checkpoint inhibitor therapy versus dual targeted therapy of untreated metastatic BRAF-mutant melanoma: a systematic review of randomised controlled trials
- Approved dual targeted therapy combinations include encorafenib plus binimetinib, vemurafenib plus cobimetinib, and dabrafenib plus trametinib. — Dual checkpoint inhibitor therapy versus dual targeted therapy of untreated metastatic BRAF-mutant melanoma: a systematic review of randomised controlled trials
- Dual BRAF and MEK inhibition improves response rates, delays resistance, and reduces toxicity compared with BRAF inhibition alone. — Dual checkpoint inhibitor therapy versus dual targeted therapy of untreated metastatic BRAF-mutant melanoma: a systematic review of randomised controlled trials
- Dual targeted therapy adverse events most often affect the skin and also include fever and gastrointestinal symptoms. — Dual checkpoint inhibitor therapy versus dual targeted therapy of untreated metastatic BRAF-mutant melanoma: a systematic review of randomised controlled trials